Ra Pharmaceuticals Inc (NASDAQ:RARX) – Analysts at Svb Leerink dropped their FY2020 earnings estimates for Ra Pharmaceuticals in a report released on Wednesday, July 10th. Svb Leerink analyst D. Ha now anticipates that the company will earn ($2.73) per share for the year, down from their prior forecast of ($2.57). Svb Leerink currently has a “Outperform” rating and a $33.00 target price on the stock.
Other equities analysts also recently issued reports about the stock. BidaskClub raised shares of Misonix from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 3rd. Raymond James decreased their price target on shares of Marathon Petroleum from $90.00 to $85.00 and set a “strong-buy” rating on the stock in a research note on Wednesday, April 10th. Zacks Investment Research raised shares of Eutelsat Communications from a “hold” rating to a “strong-buy” rating and set a $21.00 price target on the stock in a research note on Wednesday, June 12th. Jefferies Financial Group reissued a “buy” rating and issued a GBX 1,453 ($18.99) price target on shares of in a research note on Tuesday, June 18th. Finally, Leerink Swann set a $5.00 price target on shares of Tocagen and gave the stock a “hold” rating in a research note on Wednesday, May 22nd. One analyst has rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $37.73.
Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.47) by $0.02.
A number of institutional investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers boosted its holdings in shares of Ra Pharmaceuticals by 45.0% during the 4th quarter. Rhumbline Advisers now owns 20,725 shares of the company’s stock valued at $377,000 after acquiring an additional 6,432 shares in the last quarter. Prudential Financial Inc. acquired a new stake in shares of Ra Pharmaceuticals during the 4th quarter valued at $3,251,000. BlackRock Inc. boosted its holdings in shares of Ra Pharmaceuticals by 29.0% during the 4th quarter. BlackRock Inc. now owns 2,645,261 shares of the company’s stock valued at $48,142,000 after acquiring an additional 595,328 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Ra Pharmaceuticals by 44.8% during the 4th quarter. Bank of New York Mellon Corp now owns 77,818 shares of the company’s stock valued at $1,417,000 after acquiring an additional 24,059 shares in the last quarter. Finally, Raymond James & Associates acquired a new stake in shares of Ra Pharmaceuticals during the 4th quarter valued at $290,000. Hedge funds and other institutional investors own 94.97% of the company’s stock.
In related news, insider Simon Read sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, June 18th. The shares were sold at an average price of $22.25, for a total transaction of $222,500.00. Following the completion of the sale, the insider now directly owns 8,521 shares in the company, valued at $189,592.25. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Alonso Ricardo sold 2,857 shares of the firm’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $23.72, for a total transaction of $67,768.04. Following the sale, the insider now owns 11,428 shares of the company’s stock, valued at $271,072.16. The disclosure for this sale can be found here. 4.30% of the stock is currently owned by company insiders.
Ra Pharmaceuticals Company Profile
Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.
Featured Story: What impact do institutional investors have on markets?
Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.